News

  To enhance care for the growing number of people with Alzheimer’s and other dementia, the U.S. Department of Health and Human Services (HHS) has awarded the University of Oklahoma Health Sciences Center a $3.75 million grant. The grant will establish a partner-reliant program designed to better educate…

Spontaneous seizures reduce the production of new brain cells, and result in poor spatial discrimination — a common occurrence in people with Alzheimer’s disease, according to a mouse study. The study, “Early Seizure Activity Accelerates Depletion of Hippocampal Neural Stem Cells and Impairs Spatial Discrimination in an Alzheimer’s…

A diet low in carbohydrates may have cognitive benefits for older adults with mild cognitive impairment, a small study suggests. “Preliminary Report on the Feasibility and Efficacy of the Modified Atkins Diet for Treatment of Mild Cognitive Impairment and Early Alzheimer’s Disease” was published in the Journal…

Women who are carriers of the ApoE4 gene — a major genetic risk factor for the development of a late-onset form of Alzheimer’s disease, are more susceptible than men to accumulating toxic tau protein aggregates in the brain, a study suggests. This finding was shared in a study, “…

Regardless of sex, people younger than age 65 who have a first-degree relative with Alzheimer’s disease generally showed poorer verbal and memory skills on a web-based test than their peers without this family history, a study’s results show. The study, “Family history of Alzheimer’s disease alters cognition and is…

Long-term antibiotic treatment, aimed at altering the bacterial population in the gut, was found to reduce the inflammation and amyloid plaque formation that is a hallmark of Alzheimer’s disease — but only in male mice. The same treatment had no effect on female mice, a study found. The…

Genentech, a subsidiary of Roche, has launched a new substudy to learn more about the progression of early-onset familial Alzheimer’s disease, as part of its ongoing Alzheimer’s Prevention Initiative (API)…

A Phase 2a trial testing Oryzon’s investigational therapy vafidemstat for Alzheimer’s disease has enrolled its first patient in the U.S. The trial (NCT03867253), called ETHERAL-US, is an extension of the European trial (2017-004893-32), currently ongoing at 17 sites in the U.K., France, and Spain. Oryzon is…

A vaccine produced using virus-like particles was able to improve cognitive functioning and reduce the accumulation of tau protein aggregates — a hallmark of Alzheimer’s disease — in a mouse model of the disease, a study shows. The study, “Qß Virus-like particle-based vaccine induces robust immunity and protects against…

A connection discovered between Alzheimer’s and the bacteria that cause gum disease suggests that improved oral hygiene may decrease the risk of developing the disorder, a study reports. The study, “Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors,” was…